Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

in significant suppression of bone remodeling. The significance of these findings is unknown. The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw (ONJ), atypical fractures and delayed fracture healing. ONJ has been reported in patients with Prolia. Patients should be monitored for these adverse outcomes. The most common adverse reactions (> 5 percent and more common than placebo) were back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia and cystitis. Pancreatitis has also been reported with Prolia.

Important EU Safety Information

The most common adverse reactions with Prolia were urinary tract infection, upper respiratory tract infection, sciatica, cataracts, constipation, rash and pain in extremity. The most serious adverse reactions were those of skin infections, predominantly cellulitis, reported more commonly in the Prolia group compared with placebo (0.4 percent vs. 0.1 percent) in postmenopausal osteoporosis studies. In breast and prostate cancer studies, serious adverse reactions of skin infection were similar in the Prolia and placebo groups (0.6 percent vs. 0.6 percent). In the Phase 3 placebo-controlled clinical trial in patients with prostate cancer receiving ADT, an imbalance in cataract adverse events was observed with Prolia compared with placebo (4.7 percent vs. 1.2 percent placebo). No imbalance in cataract adverse events was observed in postmenopausal women with osteoporosis or in women undergoing aromatase inhibitor therapy for nonmetastatic breast cancer.

Prolia may lead to hypocalcaemia. Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. ONJ has been reported rarely in clinical studies in patients receiving denosumab at a dose of 60 mg every 6 months for osteoporosis.

Denosumab Commercialization Collaborations

I
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... LONDON , BERLIN and ... The global market has the potential to grow to ... leading provider of market research reports has announced pharma industry ... Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable ... in terms of US pricing structures and the anticipated approval ...
(Date:9/15/2014)... GENEVE , September 15, 2014 /PRNewswire/ ... des principaux fabricants européens de sortir ou ... marché ou au soutien réglementaire de la ... alcaloïdes tropaniques comme principes pharmaceutiques actifs (API), ... la nortropine, le méthylbromure d,homatropine, le bromhydrate d,homatropine, ...
(Date:9/14/2014)... DIEGO , Sept. 14, 2014 HUYA ... global development of China,s pharmaceutical ... Institute of Pharmaceutical Research (TIPR) to develop medical ... and the western world, for global markets. ... venture, to be known as TIPR-HUYA Advancing Innovative Medicines ...
Breaking Medicine Technology:Monoclonal Antibodies Market for Gastric and Esophageal Cancers to Double by 2019 2Monoclonal Antibodies Market for Gastric and Esophageal Cancers to Double by 2019 3Alchem International s'engage à poursuivre et étendre la production des principes pharmaceutiques actifs contenant des alcaloïdes tropaniques et à soutenir la réglementation pour combler l'écart d'approvisionnement 2Alchem International s'engage à poursuivre et étendre la production des principes pharmaceutiques actifs contenant des alcaloïdes tropaniques et à soutenir la réglementation pour combler l'écart d'approvisionnement 3HUYA Bioscience International and TIPR Announce Joint Venture to Develop Medical Innovation for Global Markets 2HUYA Bioscience International and TIPR Announce Joint Venture to Develop Medical Innovation for Global Markets 3HUYA Bioscience International and TIPR Announce Joint Venture to Develop Medical Innovation for Global Markets 4
... (Nasdaq: ARAY ), the premier radiation ... Especialidad in Monterrey, Mexico has starting treating patients with ... is the first center in Mexico now offering patients ... anywhere in the body. The CyberKnife System ...
... Jan. 17, 2012  Ventana Medical Systems, Inc. (Ventana), ... that it has entered into a strategic collaboration ... a molecular companion diagnostic test intended to identify ... Bayer antibody-drug conjugate (ADC). Ventana,s diagnostic immunohistochemistry platform ...
Cached Medicine Technology:First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 3First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 4Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy 2Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy 3
(Date:9/15/2014)... September 15, 2014 Insurers across ... that bring providers on board as partners to ... When bundled payment programs are designed properly they ... incentivize hospitals to work collaboratively with providers, and ... On Sept. 24, the Atlantic Information Services webinar, ...
(Date:9/15/2014)... With a simple swab of the cheek, the ... to help personalize the treatment for patients with vascular disorders, ... approach to medicine is preventive care. But, it can be ... respond to specific drugs. A simple cheek swab test can ... physician to tailor medical therapy and optimize outcomes. , “By ...
(Date:9/15/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on sterile drug products ... FDA, the Agency announced on September 9, that it ... recall of all lots of its purportedly ... expired due to lack of sterility assurance. , In ...
(Date:9/15/2014)... Fancyflyingfox.com, the distinguished wedding dress manufacturer and ... beach wedding dresses . All clients can enjoy a ... up to 70 percent off. According to the company’s ... its loyal customers by launching the current sale. ... 300 different styles of special occasion gowns are provided. ...
(Date:9/14/2014)... 2014 Skin becomes dryer with age. Some ... and not moisturizing properly. However, there are inevitable internal factors ... for. , Two main reasons this occurs: , 1) Loss ... in the skin , During the aging process, skin produces ... responsible for important moisture retention and radiance of skin. ...
Breaking Medicine News(10 mins):Health News:Sept. 24 Webinar to Profile Geisinger Health System, BCBS of North Carolina’s Successful Bundled-Payment Programs 2Health News:Center for Vascular Medicine Offers Genetic Testing For Personalized Vascular Care 2Health News:FDA Requests Recall of Sterile Drug Products by Downing Labs (aka NuVision Pharmacy): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Great Discounts On Beach Wedding Dresses Announced By Fancyflyingfox.com Now 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3
... when added to existing meds, study finds , , ... helps relieve neuropathic pain in people with HIV, ... of Medicine study. , It included 28 HIV ... by opiates or other pain relievers. The researchers ...
... Increases 2008 Net Sales Projections; Affirms Top End of Adjusted* ... Earnings Guidance --, ... global specialty pharmaceutical and medication,delivery company, today reported results for the second quarter ... during the second quarter of 2008, compared to $869.3 ...
... Inclusion for Key, Emerging Biologic Agents That Will Launch ... Years, According to a ... 6 Decision Resources, one of the,world,s leading research ... 89 percent of surveyed rheumatologists,anticipate prescribing Roche/Chugai,s Actemra, following ...
... Aduromed Begins Next Step in Corporate Evolution, Restructuring the Company ... and Augmenting its Board and Management Team, ... Board: ADRM) a leading manufacturer of medical waste,treatment systems, today ... raise of $3.8 million of new equity capital. As,part of ...
... Software, Inc. today,announced the worldwide launch of iFastrack, ... software for reducing business,risk by tracking insurance certificates ... to manage their risk from,uninsured contractors, vendors or ... proof of insurance at the onset of a ...
... Increase Revenues by Up to $2 Million This ... Corporation (OTC,Bulletin Board: BDRR), a medical imaging and ... Imaging, Inc. has entered into,a joint venture (JV) ... Basic Solutions, Inc. will offer mobile cardiac stress ...
Cached Medicine News:Health News:Medicinal Marijuana Eases Neuropathic Pain in HIV 2Health News:Hospira Reports Second-Quarter 2008 Results 2Health News:Hospira Reports Second-Quarter 2008 Results 3Health News:Hospira Reports Second-Quarter 2008 Results 4Health News:Hospira Reports Second-Quarter 2008 Results 5Health News:Hospira Reports Second-Quarter 2008 Results 6Health News:Hospira Reports Second-Quarter 2008 Results 7Health News:Hospira Reports Second-Quarter 2008 Results 8Health News:Hospira Reports Second-Quarter 2008 Results 9Health News:Hospira Reports Second-Quarter 2008 Results 10Health News:Hospira Reports Second-Quarter 2008 Results 11Health News:Hospira Reports Second-Quarter 2008 Results 12Health News:Hospira Reports Second-Quarter 2008 Results 13Health News:Hospira Reports Second-Quarter 2008 Results 14Health News:Hospira Reports Second-Quarter 2008 Results 15Health News:Hospira Reports Second-Quarter 2008 Results 16Health News:Hospira Reports Second-Quarter 2008 Results 17Health News:Hospira Reports Second-Quarter 2008 Results 18Health News:Hospira Reports Second-Quarter 2008 Results 19Health News:Hospira Reports Second-Quarter 2008 Results 20Health News:Hospira Reports Second-Quarter 2008 Results 21Health News:Hospira Reports Second-Quarter 2008 Results 22Health News:Hospira Reports Second-Quarter 2008 Results 23Health News:Hospira Reports Second-Quarter 2008 Results 24Health News:Hospira Reports Second-Quarter 2008 Results 25Health News:Hospira Reports Second-Quarter 2008 Results 26Health News:Hospira Reports Second-Quarter 2008 Results 27Health News:Hospira Reports Second-Quarter 2008 Results 28Health News:Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis 2Health News:Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis 3Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 2Health News:Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital 3Health News:GG-One Software Announces iFastrack to Help Avoid Insurance Disasters 2Health News:Bederra Corp.'s Lumar Imaging Division Enters Into Joint Venture With Basic Solutions 2
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Manage and Retrieve a ... DVMR- office, the first digital ... the physician's office environment. DVMR ... of high-resolution cameras for simple ...
Research Grade Microscope Camera from ImagingPlanet Research Microscopy Group, a superior imaging technology that delivers increased image resolution and precise color accuracy at an affordable pric...
Medicine Products: